R-(+)-Etomoxir
CAS: 124083-20-1
Ref. 3D-FE23200
2mg | Descatalogado | ||
5mg | Descatalogado | ||
10mg | Descatalogado | ||
25mg | Descatalogado | ||
50mg | Descatalogado |
Información del producto
- (R)-2-[6-(4-Chlorophenoxy)hexyl]oxiranecarboxylic acid
- ethyl ester
- (R)-(+)-Etomoxir
- (R)-Ethyl 2-(6-(4-chlorophenoxy)hexyl)oxirane-2-carboxylate
- 2-Oxiranecarboxylic acid, 2-[6-(4-chlorophenoxy)hexyl]-, ethyl ester, (2R)-
- Ethyl (+)-(R)-2-(6-(p-chlorophenoxy)hexyl)glycidate
- Etomoxir [INN]
- Oxiranecarboxylic acid, 2-[6-(4-chlorophenoxy)hexyl]-, ethyl ester, (2R)-
- Oxiranecarboxylic acid, 2-[6-(4-chlorophenoxy)hexyl]-, ethyl ester, (R)-
- Unii-Msb3Dd2Xp6
- Ver más sinónimos
- ethyl (2R)-2-[6-(4-chlorophenoxy)hexyl]oxirane-2-carboxylate
- ethyl (2S)-2-[6-(4-chlorophenoxy)hexyl]oxirane-2-carboxylate
- Etomoxir
Etomoxir is a potent inhibitor of the mitochondrial enzyme, fatty acid: 2-enoyl-CoA reductase. This enzyme catalyzes the conversion of long-chain acyl-CoA to acetyl-CoA, which is required for the synthesis of mitochondrial membrane phospholipids and cardiolipin. Etomoxir inhibits this activity and consequently prevents the production of ATP. It also inhibits oxidative phosphorylation in isolated mitochondria and reduces locomotor activity in rats. Etomoxir has been shown to have inhibitory properties on human malignant brain cells as well as breast cancer cells (MDA-MB-231).